JeffreySSagerMDMSc

Clinical Trials

• Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension Start of enrollment: 2008 May 01

  Completed

  Phase 3

• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Jul 01

  Terminated

  Phase 3

• Ventavis® Registry Protocol Start of enrollment: 2009 Mar 01

  Terminated

• Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1 Start of enrollment: 2012 Dec 01

  Completed

  Phase 1

• Beraprost-314d Added-on to Tyvaso® (BEAT) Start of enrollment: 2013 May 31

  Completed

  Phase 3

• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis Start of enrollment: 2016 Feb 01

  Withdrawn

  Phase 2

• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Start of enrollment: 2017 Feb 03

  Completed

  Phase 2, Phase 3

• An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Start of enrollment: 2016 Sep 15

  Terminated

  Phase 2, Phase 3

• A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) Start of enrollment: 2016 Apr 01

  Completed

  Phase 2

• Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) Start of enrollment: 2016 Dec 01

  Terminated

  Phase 2

• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction Start of enrollment: 2017 Aug 15

  Terminated

  Phase 3

• Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF Start of enrollment: 2018 Jan 30

  Terminated

  Phase 3

• ADAPT - A Patient Registry of the Real-world Use of Orenitram® Start of enrollment: 2017 Jul 18

  Active, not recruiting

• Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) Start of enrollment: 2022 Mar 18

  Recruiting

  Phase 3

• A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) Start of enrollment: 2021 Dec 29

  Recruiting

  Phase 2

• A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) Start of enrollment: 2021 May 12

  Recruiting

  Phase 3

• A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) Start of enrollment: 2021 Jul 16

  Active, not recruiting

• Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2021 Apr 05

  Recruiting

  Phase 2

• A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2) Start of enrollment: 2021 Mar 15

  Completed

  Phase 2

• Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis Start of enrollment: 2020 Mar 03

  Completed

  Phase 2

• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Start of enrollment: 2020 Jun 30

  Recruiting

  Phase 3

• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Start of enrollment: 2018 Aug 30

  Recruiting

  Phase 3

• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Start of enrollment: 2019 Sep 23

  Enrolling by invitation

  Phase 3

• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) Start of enrollment: 2023 Dec 28

  Recruiting

  Phase 3

• Join now to see all